1
|
García-Prieto AM, Verdalles Ú, de José AP, Arroyo D, Aragoncillo I, Barbieri D, Camacho RE, Goicoechea M. Renin-angiotensin-aldosterone system blockers effect in chronic kidney disease progression in hypertensive elderly patients without proteinuria: PROERCAN trial. Hipertens Riesgo Vasc 2024; 41:95-103. [PMID: 38508877 DOI: 10.1016/j.hipert.2023.11.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Revised: 11/20/2023] [Accepted: 11/22/2023] [Indexed: 03/22/2024]
Abstract
INTRODUCTION Evidence about nefroprotective effect with RAAS blockers in elderly patients with chronic kidney disease (CKD) without proteinuria is lacking. The primary outcome of our study is to evaluate the impact of RAAS blockers in CKD progression in elderly patients without proteinuria. MATERIALS AND METHODS Multicenter open-label, randomized controlled clinical trial including patients over 65 year-old with hypertension and CKD stages 3-4 without proteinuria. Patients were randomized in a 1:1 ratio to either receive RAAS blockers or other antihypertensive drugs and were followed up for three years. Primary outcome is estimated glomerular filtration rate (eGFR) decline at 3 years. Secondary outcome measures include BP control, renal and cardiovascular events and mortality. RESULTS 88 patients were included with a mean age of 77.9±6.1 years and a follow up period of 3 years: 40 were randomized to RAAS group and 48 to standard treatment. Ethiology of CKD was: 53 vascular, 16 interstitial and 19 of unknown ethiology. In the RAAS group eGFR slope during follow up was -4.3±1.1ml/min, whereas in the standard treatment group an increase on eGFR was observed after 3 years (+4.6±0.4ml/min), p=0.024. We found no differences in blood pressure control, number of antihypertensive drugs, albuminuria, potassium serum levels, incidence of cardiovascular events nor mortality during the follow up period. CONCLUSIONS In elderly patients without diabetes nor cardiopathy and with non proteinuric CKD the use of RAAS blockers does not show a reduction in CKD progression. The PROERCAN (PROgresión de Enfermedad Renal Crónica en ANcianos) trial (trial registration: NCT03195023).
Collapse
Affiliation(s)
- A M García-Prieto
- RICORS 2040, Instituto de Salud Carlos III, Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
| | - Ú Verdalles
- RICORS 2040, Instituto de Salud Carlos III, Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - A P de José
- RICORS 2040, Instituto de Salud Carlos III, Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - D Arroyo
- RICORS 2040, Instituto de Salud Carlos III, Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - I Aragoncillo
- RICORS 2040, Instituto de Salud Carlos III, Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - D Barbieri
- RICORS 2040, Instituto de Salud Carlos III, Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - R E Camacho
- Servicio de Nefrología, Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain
| | - M Goicoechea
- RICORS 2040, Instituto de Salud Carlos III, Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| |
Collapse
|
2
|
Caravaca-Fontán F, Stevens K, Padrón M, Huerta A, Montomoli M, Villa J, González F, Vega C, López Mendoza M, Fernández L, Shabaka A, Rodríguez-Moreno A, Martín-Gómez A, Labrador PJ, Molina Andújar A, Prados Soler MC, Martín-Penagos L, Yerovi E, Medina Zahonero L, De La Flor JC, Mon C, Ibernon M, Rodríguez Gómez A, Miquel R, Sierra M, Mascarós V, Luzardo L, Papasotiriou M, Arroyo D, Verdalles Ú, Martínez-Miguel P, Ramírez-Guerrero G, Pampa-Saico S, Moral Berrio E, Canga JLP, Tarragón B, Fraile Gómez P, Regidor D, Relea J, Xipell M, Andrades Gómez C, Navarro M, Álvarez Á, Rivas B, Quintana LF, Gutiérrez E, Pérez-Valdivia MÁ, Odler B, Kronbichler A, Geddes C, Anders HJ, Floege J, Fernández-Juárez G, Praga M. Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis. Nephrol Dial Transplant 2024; 39:328-340. [PMID: 37550217 DOI: 10.1093/ndt/gfad175] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Indexed: 08/09/2023] Open
Abstract
BACKGROUND The role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the management glomerular/systemic autoimmune diseases with proteinuria in real-world clinical settings is unclear. METHODS This is a retrospective, observational, international cohort study. Adult patients with biopsy-proven glomerular diseases were included. The main outcome was the percentage reduction in 24-h proteinuria from SGLT2i initiation to 3, 6, 9 and 12 months. Secondary outcomes included percentage change in estimated glomerular filtration rate (eGFR), proteinuria reduction by type of disease and reduction of proteinuria ≥30% from SGLT2i initiation. RESULTS Four-hundred and ninety-three patients with a median age of 55 years and background therapy with renin-angiotensin system blockers were included. Proteinuria from baseline changed by -35%, -41%, -45% and -48% at 3, 6, 9 and 12 months after SGLT2i initiation, while eGFR changed by -6%, -3%, -8% and -10.5% at 3, 6, 9 and 12 months, respectively. Results were similar irrespective of the underlying disease. A correlation was found between body mass index (BMI) and percentage proteinuria reduction at last follow-up. By mixed-effects logistic regression model, serum albumin at SGLT2i initiation emerged as a predictor of ≥30% proteinuria reduction (odds ratio for albumin <3.5 g/dL, 0.53; 95% CI 0.30-0.91; P = .02). A slower eGFR decline was observed in patients achieving a ≥30% proteinuria reduction: -3.7 versus -5.3 mL/min/1.73 m2/year (P = .001). The overall tolerance to SGLT2i was good. CONCLUSIONS The use of SGLT2i was associated with a significant reduction of proteinuria. This percentage change is greater in patients with higher BMI. Higher serum albumin at SGLT2i onset is associated with higher probability of achieving a ≥30% proteinuria reduction.
Collapse
Affiliation(s)
| | - Kate Stevens
- Department of Nephrology and Transplantation, Queen Elizabeth University Hospital, Glasgow, UK
| | - Maite Padrón
- Department of Nephrology, Complejo Hospitalario de Toledo, Toledo, Spain
| | - Ana Huerta
- Department of Nephrology, Hospital Universitario Puerta de Hierro, Madrid, Spain
| | - Marco Montomoli
- Department of Nephrology, Hospital Clínico Universitario de Valencia, Valencia, Spain
| | - Juan Villa
- Department of Nephrology, Hospital Universitario de Badajoz, Badajoz, Spain
| | - Fayna González
- Department of Nephrology, Hospital Doctor Negrín, Gran Canaria, Spain
| | - Cristina Vega
- Department of Nephrology, Hospital Universitario La Paz, Madrid, Spain
| | - Manuel López Mendoza
- Department of Nephrology, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - Loreto Fernández
- Department of Nephrology, Complejo Hospitalario de Navarra, Navarra, Spain
| | - Amir Shabaka
- Department of Nephrology, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain
| | | | | | - Pedro J Labrador
- Department of Nephrology, Hospital San Pedro de Alcántara, Cáceres, Spain
| | | | | | - Luis Martín-Penagos
- Department of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Estefanía Yerovi
- Department of Nephrology, Hospital Universitario de Burgos, Burgos, Spain
| | | | | | - Carmen Mon
- Department of Nephrology, Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain
| | - Meritxell Ibernon
- Department of Nephrology, Hospital Sant Joan Despí Moisès Broggi, Barcelona, Spain
| | | | - Rosa Miquel
- Department of Nephrology, Hospital Universitario Canarias, Tenerife, Spain
| | - Milagros Sierra
- Department of Nephrology, Hospital San Pedro de Logroño, La Rioja, Logroño, Spain
| | - Victoria Mascarós
- Department of Nephrology, Hospital Francesc de Borja, Gandia, Valencia, Spain
| | - Leonella Luzardo
- Department of Nephrology, Hospital de Clínicas "Dr Manuel Quintela", Universidad de la República, Montevideo, Uruguay
| | | | - David Arroyo
- Department of Nephrology, Hospital Universitario Gregorio Marañón, Madrid, Spain
| | - Úrsula Verdalles
- Department of Nephrology, Hospital Universitario Gregorio Marañón, Madrid, Spain
| | | | | | - Saúl Pampa-Saico
- Department of Nephrology, Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain
| | - Esperanza Moral Berrio
- Department of Nephrology, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
| | - José Luis Pérez Canga
- Department of Nephrology, Hospital Universitario San Agustín, Avilés, Asturias, Spain
| | - Blanca Tarragón
- Department of Nephrology, Hospital Universitario de Getafe, Getafe, Madrid, Spain
| | - Pilar Fraile Gómez
- Department of Nephrology, Hospital Universitario de Salamanca, Salamanca, Spain
| | - Dabaiba Regidor
- Department of Nephrology, Complejo Hospitalario de Toledo, Toledo, Spain
| | - Javier Relea
- Department of Nephrology, Hospital Universitario Puerta de Hierro, Madrid, Spain
| | - Marc Xipell
- Department of Nephrology, Hospital Clinic, Barcelona, Spain
| | | | - Maruja Navarro
- Department of Nephrology, Hospital Sant Joan Despí Moisès Broggi, Barcelona, Spain
| | - Álvaro Álvarez
- Department of Nephrology, Hospital Universitario de Badajoz, Badajoz, Spain
| | - Begoña Rivas
- Department of Nephrology, Hospital Universitario La Paz, Madrid, Spain
| | | | - Eduardo Gutiérrez
- Department of Nephrology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | | | - Balazs Odler
- Department of Medicine, University of Cambridge, Cambridge, UK
- Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
| | - Andreas Kronbichler
- Department of Medicine, University of Cambridge, Cambridge, UK
- Department of Internal Medicine IV, Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria
| | - Colin Geddes
- Department of Nephrology and Transplantation, Queen Elizabeth University Hospital, Glasgow, UK
| | - Hans-Joachim Anders
- Department of Internal Medicine IV, Hospital of the Ludwig Maximilians University, Munich, Germany
| | - Jürgen Floege
- Division of Nephrology, RWTH Aachen University Hospital, Aachen, Germany
| | | | - Manuel Praga
- Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain
- Department of Nephrology, Hospital Universitario 12 de Octubre, Madrid, Spain
| |
Collapse
|
3
|
Barbieri D, Goicoechea M, Verde E, García-Prieto A, Verdalles Ú, Pérez de José A, Delgado A, Sánchez-Niño MD, Ortiz A. Obesity, chronic kidney disease progression and the role of the adipokine C1q/TNF related protein-3. Nefrologia 2023; 43:328-334. [PMID: 36517365 DOI: 10.1016/j.nefroe.2022.02.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2021] [Accepted: 02/07/2022] [Indexed: 06/17/2023] Open
Abstract
INTRODUCTION AND AIMS Obesity is a risk factor for incident chronic kidney disease (CKD). C1q/TNF related protein 3 (CTRP3) is an adipokine with multiple effects and may modulate the association between obesity and vascular diseases. The aim of the study is to explore potential links between obesity, CTRP3 levels and CKD progression. METHODS Patients with stage 3 and 4 CKD without previous cardiovascular events were enrolled and divided into groups according to body mass index (BMI) and sex. Demographic, clinical, analytical data and CTRP3 levels were collected at baseline. During follow-up, renal events (defined as dialysis initiation, serum creatinine doubling or a 50% decrease in estimated glomerular filtration rate were registered). RESULTS 81 patients were enrolled. 27 were obese and 54 non-obese. Baseline CTRP3 was similar between both groups (90.1±23.8 vs 84.5±6.2; p=0.28). Of the sum, 54 were men and 27 women, with higher CTRP3 in women (81.4±24.7 vs 106±24.7;p<0.01). During a mean follow-up of 68 months, 15 patients had a renal event. Patients in the higher CTRP3 tertile had less events but without statistical significance (p=0.07). Obese patients in the higher CTRP3 tertile significantly had less renal events (p=0.049). By multiple regression analysis CTRP3 levels could not predict renal events (HR 0.98; CI95% 0.96-1.06). CONCLUSIONS CTRP3 levels are higher in woman than men in patients with CKD, with similar levels between obese and non obese. Higher CTRP3 levels at baseline were associated with better renal outcomes in obese patients.
Collapse
Affiliation(s)
- Diego Barbieri
- Nephrology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
| | - Marian Goicoechea
- Nephrology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Eduardo Verde
- Nephrology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Ana García-Prieto
- Nephrology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Úrsula Verdalles
- Nephrology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Ana Pérez de José
- Nephrology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Andrés Delgado
- Nephrology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | | | - Alberto Ortiz
- Nephrology Department, ISS-Fundación Jimenez Díaz, Univerisdad Autonoma de Madrid, Madrid, Spain
| |
Collapse
|
4
|
Barbieri D, Goicoechea M, Verde E, García-Prieto A, Verdalles Ú, Pérez de José A, Delgado A, Sánchez-Niño MD, Ortiz A. Obesity, chronic kidney disease progression and the role of the adipokine C1q/TNF related protein-3. Nefrologia 2022. [DOI: 10.1016/j.nefro.2022.02.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
5
|
García-Prieto AM, Verdalles Ú, Goicoechea M. Use of renin-angiotensin-aldosterone system blockade in controversial chronic kidney disease populations. Med Clin (Barc) 2021; 156:561-567. [PMID: 33757646 DOI: 10.1016/j.medcli.2020.12.025] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Revised: 12/01/2020] [Accepted: 12/02/2020] [Indexed: 02/06/2023]
Abstract
Renin-angiotensin-aldosterone system blockers have shown to be effective in controlling blood pressure and proteinuria, slowing the progression to end stage renal disease and reducing cardiovascular risk, so they are the mainstream treatment of hypertension in chronic kidney disease. Their beneficial effects have been proven in multiple randomized clinical trials on different study populations, but there has recently been some controversial data on its use in some subgroups of patients, especially those with advanced chronic kidney disease. In some other populations such as patients with non-proteinuric nephropathies or the elderly, who can be more susceptible to its adverse events, their benefits have also been questioned. The aim of the present review is to collect available published data on the effect of renin-angiotensin-aldosterone system blockers in some controversial populations and provide perspective on future research areas in this field.
Collapse
Affiliation(s)
| | - Úrsula Verdalles
- Nephrology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Marian Goicoechea
- Nephrology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Red de Investigación Renal (REDinREN), Spain
| |
Collapse
|
6
|
Goicoechea M, Sánchez Cámara LA, Macías N, Muñoz de Morales A, Rojas ÁG, Bascuñana A, Arroyo D, Vega A, Abad S, Verde E, García Prieto AM, Verdalles Ú, Barbieri D, Delgado AF, Carbayo J, Mijaylova A, Acosta A, Melero R, Tejedor A, Benitez PR, Pérez de José A, Rodriguez Ferrero ML, Anaya F, Rengel M, Barraca D, Luño J, Aragoncillo I. COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain. Kidney Int 2020; 98:27-34. [PMID: 32437770 PMCID: PMC7211728 DOI: 10.1016/j.kint.2020.04.031] [Citation(s) in RCA: 211] [Impact Index Per Article: 52.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Revised: 04/28/2020] [Accepted: 04/29/2020] [Indexed: 12/15/2022]
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia emerged in Wuhan, China in December 2019. Unfortunately, there is a lack of evidence about the optimal management of novel coronavirus disease 2019 (COVID-19), and even less is available in patients on maintenance hemodialysis therapy than in the general population. In this retrospective, observational, single-center study, we analyzed the clinical course and outcomes of all maintenance hemodialysis patients hospitalized with COVID-19 from March 12th to April 10th, 2020 as confirmed by real-time polymerase chain reaction. Baseline features, clinical course, laboratory data, and different therapies were compared between survivors and nonsurvivors to identify risk factors associated with mortality. Among the 36 patients, 11 (30.5%) died, and 7 were able to be discharged within the observation period. Clinical and radiological evolution during the first week of admission were predictive of mortality. Among the 36 patients, 18 had worsening of their clinical status, as defined by severe hypoxia with oxygen therapy requirements greater than 4 L/min and radiological worsening. Significantly, 11 of those 18 patients (61.1%) died. None of the classical cardiovascular risk factors in the general population were associated with higher mortality. Compared to survivors, nonsurvivors had significantly longer dialysis vintage, increased lactate dehydrogenase (490 U/l ± 120 U/l vs. 281 U/l ± 151 U/l, P = 0.008) and C-reactive protein levels (18.3 mg/dl ± 13.7 mg/dl vs. 8.1 mg/dl ± 8.1 mg/dl, P = 0.021), and a lower lymphocyte count (0.38 ×103/µl ± 0.14 ×103/µl vs. 0.76 ×103/µl ± 0.48 ×103/µl, P = 0.04) 1 week after clinical onset. Thus, the mortality among hospitalized hemodialysis patients diagnosed with COVID-19 is high. Certain laboratory tests can be used to predict a worsening clinical course.
Collapse
Affiliation(s)
- Marian Goicoechea
- Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Red de Investigación Renal Instituto de Salud Carlos III (ISCIII) Red temática de investigación cooperativa en salud (RETIC) Red de Investigación Renal (REDINREN) RD016/009 (FEDER funds), Madrid, Spain.
| | | | - Nicolás Macías
- Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | | | - Ángela González Rojas
- Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Arturo Bascuñana
- Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - David Arroyo
- Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Almudena Vega
- Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Soraya Abad
- Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Eduardo Verde
- Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | | | - Úrsula Verdalles
- Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Diego Barbieri
- Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Andrés Felipe Delgado
- Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Javier Carbayo
- Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Antonia Mijaylova
- Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Adriana Acosta
- Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Rosa Melero
- Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Alberto Tejedor
- Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | | | - Ana Pérez de José
- Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | | | - Fernando Anaya
- Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Manuel Rengel
- Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Daniel Barraca
- Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - José Luño
- Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Inés Aragoncillo
- Red de Investigación Renal Instituto de Salud Carlos III (ISCIII) Red temática de investigación cooperativa en salud (RETIC) Red de Investigación Renal (REDINREN) RD016/009 (FEDER funds), Madrid, Spain; Department of Nephrology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
| |
Collapse
|
7
|
García-Prieto AM, Verdalles Ú, de José AP, Verde E, Arroyo D, Aragoncillo I, Linares T, Barbieri D, Goicoechea M. The effect of renin-angiotensin-aldosterone system blockers on the progression of chronic kidney disease in hypertensive elderly patients without proteinuria: PROERCAN study. Rationale and design. Hipertens Riesgo Vasc 2020; 37:101-107. [PMID: 32156479 DOI: 10.1016/j.hipert.2020.02.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2020] [Revised: 02/19/2020] [Accepted: 02/20/2020] [Indexed: 11/26/2022]
Abstract
INTRODUCTION Blood pressure (BP) control is fundamental to the care of patients with chronic kidney disease (CKD), and is relevant at all stages of CKD. Renin-angiotensin-aldosterone system (RAAS) blockers have shown to be effective, not only in BP control but also in reducing proteinuria and slowing CKD progression. However, there is a lack of evidence for recommending RAAS blockers in elderly patients with CKD without proteinuria. The primary outcome of the present study is to evaluate the impact of RAAS blockers on CKD progression in elderly patients without proteinuria. MATERIALS AND METHODS The PROERCAN trial (trial registration, NCT03195023) is a multicentre open-label, randomized controlled clinical trial with 110 participants over 65 years-old with hypertension and CKD stages 3-4 without proteinuria. Patients will be randomized in a 1:1 ratio to either receive RAAS blockers or other antihypertensive drugs, and will be followed up for three years. Primary outcome is the estimated glomerular filtration rate (eGFR) decline at 3 years. Secondary outcomes include BP control, renal and cardiovascular events, and mortality. RESULTS AND CONCLUSIONS The design of this trial is presented here. The results will show if antihypertensive treatment with RAAS blockers has an impact on CKD progression in elderly patients without proteinuria. Any differences in BP control, cardiovascular events, and mortality with each antihypertensive treatment will be also clarified.
Collapse
Affiliation(s)
- A M García-Prieto
- Servicio Nefrología Hospital General Universitario Gregorio Marañón, Calle Doctor Esquerdo 46, 28007 Madrid, Spain.
| | - Ú Verdalles
- Servicio Nefrología Hospital General Universitario Gregorio Marañón, Calle Doctor Esquerdo 46, 28007 Madrid, Spain
| | - A P de José
- Servicio Nefrología Hospital General Universitario Gregorio Marañón, Calle Doctor Esquerdo 46, 28007 Madrid, Spain
| | - E Verde
- Servicio Nefrología Hospital General Universitario Gregorio Marañón, Calle Doctor Esquerdo 46, 28007 Madrid, Spain
| | - D Arroyo
- Servicio Nefrología Hospital General Universitario Gregorio Marañón, Calle Doctor Esquerdo 46, 28007 Madrid, Spain
| | - I Aragoncillo
- Servicio Nefrología Hospital General Universitario Gregorio Marañón, Calle Doctor Esquerdo 46, 28007 Madrid, Spain
| | - T Linares
- Servicio Nefrología Hospital General Universitario Gregorio Marañón, Calle Doctor Esquerdo 46, 28007 Madrid, Spain
| | - D Barbieri
- Servicio Nefrología Hospital General Universitario Gregorio Marañón, Calle Doctor Esquerdo 46, 28007 Madrid, Spain
| | - M Goicoechea
- Servicio Nefrología Hospital General Universitario Gregorio Marañón, Calle Doctor Esquerdo 46, 28007 Madrid, Spain; Spanish Research Network (REDINREN), Madrid, Spain
| |
Collapse
|
8
|
García-Prieto A, Goicoechea M, Linares T, Panizo N, García de Vinuesa MS, Verdalles Ú, Verde E, Pérez de José A, Luño J. Impact of anticoagulation and platelet antiaggregation on anaemia and haemorragic events in patients with chronic kidney disease stages 3 and 4. Med Clin (Barc) 2018; 151:476-480. [PMID: 29503026 DOI: 10.1016/j.medcli.2018.01.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2017] [Revised: 01/09/2018] [Accepted: 01/11/2018] [Indexed: 11/15/2022]
Abstract
BACKGROUND AND OBJECTIVE There is controversy concerning the risk/benefit of anticoagulation/antiaggregation in chronic kidney disease (CKD) patients. We analysed the impact of anticoagulation/antiaggregation on anaemia and haemorrhagic events in CKD patients. PATIENTS AND METHODS A total of 232 CKD patients stages 3 and 4 were followed during a mean follow-up time of 36.7 ± 11.6 months: 81 patients did not receive any anticoagulation or antiaggregation treatment, 91 received anticoagulation treatment and 60 patients received platelet antiaggregation. Haemorrhagic and cardiovascular events were recorded. RESULTS Haemoglobin and ferritine levels were significantly higher in patients who did not receive anticoagulation or antiaggregation (Hb 13.7 ± 1.6, 13.3 ± 1.8 and 12.7±1.9g/dl, p=0.004; ferritine 170 ± 145, 140 ± 138, 105 ± 99μg/l, p=0.023). During follow up, 36 haemorrhagic events were registered: 4in the control group, 23 in the anticoagulation group and 9in the antiaggregation group (log rank 12.5; p=0.002). In a Cox model adjusted by age, renal function and haemoglobin levels, the anticoagulation increased the risk of bleeding by 4times (HR 4.180, 1.955-8.937); p=0,001) and antiaggregation by almost 3times (HR 2.780, 1.257-6.149, p=0.012). A total of 64 cardiovascular events were registered, 21 of which were classified as atherosclerotic events: 10 in the antiaggregation group, 8in the control group and 3in the anticoagulation group (log rank: 8.351; p=0.015). Anticoagulation treatment showed a reduction in the risk of atherosclerotic events (HR 0.136, 0.033-0.551, p=0.005) while platelet antiaggregation did not modified this risk (HR 1,566, 0.569-4.308). CONCLUSIONS Anticoagulation and antiaggregation increase haemorrhagic risk in patients with CKD and worsen anaemia. Anticoagulation reduces atherosclerotic events by more than 85% while platelet antiaggregation does not modify this risk.
Collapse
Affiliation(s)
- Ana García-Prieto
- Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, España.
| | - Marian Goicoechea
- Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - Tania Linares
- Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - Nayara Panizo
- Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, España
| | | | - Úrsula Verdalles
- Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - Eduardo Verde
- Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - Ana Pérez de José
- Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - José Luño
- Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, España
| |
Collapse
|
9
|
Macías N, Abad S, Vega A, Cedeño S, Santos A, Verdalles Ú, Linares T, Aragoncillo I, Galán I, García-Prieto A, Luño J, López Gómez JM. High convective volumes are associated with improvement in metabolic profile in diabetic patients on online haemodiafiltration. Nefrologia 2018; 39:168-176. [PMID: 30467078 DOI: 10.1016/j.nefro.2018.08.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2018] [Revised: 07/10/2018] [Accepted: 08/25/2018] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND AND OBJECTIVE Online haemodiafiltration (OL-HDF) with high convective transport volumes improves patient survival in haemodialysis. Limiting the amount of convective volume has been proposed in patients with diabetes mellitus due to glucose load that is administered with replacement fluid. The objective of the study was to analyse the influence of substitution volume on the evolution of the metabolic profile and body composition of incident diabetic patients on OL-HDF. MATERIAL AND METHODS Prospective observational study in 29 incident diabetic patients on postdilution OL-HDF. Baseline data included clinical and demographic data, laboratory parameters (metabolic, nutritional and inflammatory profile) and body composition with bioimpedance spectroscopy (BIS). Laboratory parameters and mean substitution volume per session were collected every 4 months, and in 23 patients a further BIS was performed after a minimum of one year. Variations in glycosylated haemoglobin (HbA1c), triglycerides, total cholesterol, LDL-c, HDL-c, albumin, prealbumin and C reactive protein (CRP) were calculated at one year, 2 years, 3 years, and at the end of follow-up. Quarterly and annual variations were calculated as independent periods, and changes in body composition were analysed. RESULTS Age at baseline was 69.7±13.6 years, 62.1% were male, 72.3±13.9kg, 1.78±0.16m2, with 48 (35.5-76) months on dialysis. Approximately 81.5% received insulin, 7.4% antidiabetic drugs and 51.9% statins. Mean substitution volume was 26.9±2.9L/session and follow-up period (time on OL-HDF) was 40.4±26 months. A significant correlation was observed between mean substitution volume and the increase in HDL-c (r=0.385, p=0.039) and prealbumin levels (r=0.404, p=0.003) throughout follow-up. Moreover, substitution volume was correlated with a reduction in CRP levels at one year (r=-0.531, p=0.005), 2 years (r=-0.463, p=0.046), and at the end of follow-up (r=-0.498, p=0.007). Patients with mean substitution volume >26.9L/session had a higher reduction in triglycerides and CRP, and an increase in HDL-c levels. These patients with >26.9L/session finished the study with higher HDL-c (48.1±9.4mg/dL vs. 41.2±11.6mg/dL, p=0.025) and lower CRP levels (0.21 [0.1-2.22] mg/dL vs. 1.01 [0.15-6.96] mg/dL, p=0.001), with no differences at baseline. Quarterly comparisons between substitution volume and laboratory changes [n=271] showed a significant correlation with a reduction in HbA1c (r=-0.146, p=0.021). Similar findings were obtained with annual comparisons [n=72] (r=-0.237, p=0.045). An annual mean substitution volume over 26.6L/session (29.3±1.7L/session vs. 23.9±1.9L/session) was associated with a reduction in HbA1c (-0.51±1.24% vs. 0.01±0.88%, p=0.043). No correlation was observed between substitution volume and changes in weight, body mass index or BIS parameters. CONCLUSION There is not enough evidence to restrict convective transport in diabetic patients on OL-HDF due to the glucose content of the replacement fluid.
Collapse
Affiliation(s)
- Nicolás Macías
- Servicio de Nefrología, Hospital Gregorio Marañón, Madrid, España.
| | - Soraya Abad
- Servicio de Nefrología, Hospital Gregorio Marañón, Madrid, España
| | - Almudena Vega
- Servicio de Nefrología, Hospital Gregorio Marañón, Madrid, España
| | - Santiago Cedeño
- Servicio de Nefrología, Hospital Gregorio Marañón, Madrid, España
| | - Alba Santos
- Servicio de Nefrología, Hospital Gregorio Marañón, Madrid, España
| | - Úrsula Verdalles
- Servicio de Nefrología, Hospital Gregorio Marañón, Madrid, España
| | - Tania Linares
- Servicio de Nefrología, Hospital Gregorio Marañón, Madrid, España
| | - Inés Aragoncillo
- Servicio de Nefrología, Hospital Gregorio Marañón, Madrid, España
| | - Isabel Galán
- Servicio de Nefrología, Hospital Gregorio Marañón, Madrid, España
| | | | - José Luño
- Servicio de Nefrología, Hospital Gregorio Marañón, Madrid, España
| | | |
Collapse
|
10
|
Galán I, Verdalles Ú, García de Vinuesa M, Quiroga B, Goicoechea M, Pérez A, Verde E, Luño J. Impact of the application of the JNC 8 and KDIGO-2013 guidelines on hypertension and lipid control in a Nephrology outpatient clinic. Nefrologia 2018; 38:379-385. [PMID: 30032855 DOI: 10.1016/j.nefro.2017.10.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2015] [Revised: 07/31/2017] [Accepted: 10/23/2017] [Indexed: 01/19/2023] Open
Abstract
OBJECTIVE Observational retrospective study with consecutive patients with CKD to assess the degree of accomplishment of the therapeutic objectives in hypertension and dyslipidaemia recommended by JNC 8 and KDIGO-2013 CKD guidelines the impact of their implementation compared with previous guidelines. RESULTS 618 patients were included, mean age 67±15 years, 61.33% male. Mean eGFR was 45.99±18.94ml/min, with median albumin/creatinine 26 (0-151)mg/g. A total of 87.6% received antihypertensive treatment and 50.2% received statins. According to KDIGO guidelines, 520 patients (84.14%) should receive statins, but only 304 (58.46%) were receiving them. Patients on statin treatment had more diabetes and hypertension, and a greater cardiovascular history and lower levels of total and LDL-cholesterol. A total of 97.7% of patients were under 60 years of age or had eGFR<60ml/min/1.73m2 or were diabetic, so according to the JNC 8 report, they should have a target blood pressure<140/90mmHg. A total of 289 patients did (47.85%). According to the JNC 7 report, this group had a tighter target blood pressure<130/90mmHg, reducing the number of patients who fulfilled the target: 136 (22.52%). Patients reclassified were older, had a greater cardiovascular history and less DM. CONCLUSION The new KDIGO guidelines for dyslipidaemia treatment increase the indication of statin therapy, especially in patients at high cardiovascular risk. The JNC 8 guidelines improve the percentage of patients with controlled blood pressure, especially the elderly and patients with increased cardiovascular risk, in whom the target blood pressure is currently controversial.
Collapse
Affiliation(s)
- Isabel Galán
- Hospital General Universitario Gregorio Marañón, Madrid, España.
| | | | | | - Borja Quiroga
- Hospital General Universitario Gregorio Marañón, Madrid, España
| | | | - Ana Pérez
- Hospital General Universitario Gregorio Marañón, Madrid, España
| | - Eduardo Verde
- Hospital General Universitario Gregorio Marañón, Madrid, España
| | - José Luño
- Hospital General Universitario Gregorio Marañón, Madrid, España
| |
Collapse
|
11
|
Barbieri D, Sánchez-Niño MD, Goicoechea MA, Ortiz A, Verde E, Verdalles Ú, Perez de José A, Garcia-Prieto A, Torres E, Hernández Coronado A, Luño J. SP264C1Q TNF RELATED PROTEIN 1, OBESITY AND PROGRESSION OF CHRONIC KIDNEY DISEASE. Nephrol Dial Transplant 2018. [DOI: 10.1093/ndt/gfy104.sp264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Diego Barbieri
- Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | | | | | - Alberto Ortiz
- Nephrology, Instituto de Investigación Sanitaria, Fundación Jiménez Díaz, Madrid, Spain
| | - Eduardo Verde
- Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Úrsula Verdalles
- Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Ana Perez de José
- Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Ana Garcia-Prieto
- Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Esther Torres
- Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | | | - Jose Luño
- Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| |
Collapse
|
12
|
Cedeño Mora S, Goicoechea M, Torres E, Verdalles Ú, Pérez de José A, Verde E, García de Vinuesa S, Luño J. Cardiovascular risk prediction in chronic kidney disease patients. Nefrologia 2017; 37:293-300. [PMID: 28495396 DOI: 10.1016/j.nefro.2016.10.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2016] [Revised: 09/29/2016] [Accepted: 10/05/2016] [Indexed: 01/17/2023] Open
Abstract
INTRODUCTION Scores underestimate the prediction of cardiovascular risk (CVR) as they are not validated in patients with chronic kidney disease (CKD). Two of the most commonly used scores are the Framingham Risk Score (FRS-CVD) and the ASCVD (AHA/ACC 2013). The aim of this study is to evaluate the predictive ability of experiencing a cardiovascular event (CVE) via these 2scores in the CKD population. MATERIAL AND METHODS Prospective, observational study of 400 prevalent patients with CKD (stages 4 and 5 according the KDOQI; not on dialysis). Cardiovascular risk was calculated according to the 2scores and the predictive capacity of cardiovascular events (atherosclerotic events: myocardial infarction, ischaemic and haemorrhagic stroke, peripheral vascular disease; and non-atherosclerotic events: heart failure) was analysed. RESULTS Forty-nine atherosclerotic cardiovascular events occurred in 40.3±6.6 months of follow-up. Most of the patients were classified as high CVR by both scores (59% by the FRS-CVD and 75% by the ASCVD). All cardiovascular events occurred in the high CVR patients and both scores (FRS-CVD log-rank 12.2, P<.001, HR 3.1 [95% CI: 1.3-7.1] P: 0.006 and ASCVD log-rank 8.5 P<.001, HR 3.2 [95% CI: 1.1-9.4] P: 0.03) were independent predictors adjusted to renal function, albuminuria and previous cardiovascular events. CONCLUSION The cardiovascular risk scores (FRS-CVD and ASCVD [AHA/ACC 2013]) can estimate the probability of atherosclerotic cardiovascular events in patients with CKD regardless of renal function, albuminuria and previous cardiovascular events.
Collapse
Affiliation(s)
- Santiago Cedeño Mora
- Departamento de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, España.
| | - Marian Goicoechea
- Departamento de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - Esther Torres
- Departamento de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - Úrsula Verdalles
- Departamento de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - Ana Pérez de José
- Departamento de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - Eduardo Verde
- Departamento de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, España
| | | | - José Luño
- Departamento de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, España
| |
Collapse
|
13
|
Quiroga B, Galán I, García de Vinuesa S, Goicoechea M, Verdalles Ú, Luño J. Interarm systolic blood pressure as a predictor of cardiovascular events in patients with chronic kidney disease. Nephrol Dial Transplant 2015; 30:801-6. [PMID: 25753805 DOI: 10.1093/ndt/gfv059] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Accepted: 02/10/2015] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Increased interarm systolic blood pressure difference (IASBPD) is associated with mortality and cardiovascular (CV) events both in the general population and in patients at high CV risk. The aim of the present study was to assess the value of IASBPD ≥ 10 mmHg for predicting CV events in patients with chronic kidney disease (CKD). METHODS The study sample comprised 652 patients with CKD (age 67 ± 15 years, 58.1% men). Follow-up was 19 ± 5 months. We recorded increased IASBPD and related factors and assessed the predictive value of this variable for CV events. RESULTS We recorded diabetes mellitus in 136 patients (20.8%), history of CV disease in 213 (32.6%) and dyslipidaemia in 327 (50.1%). The mean glomerular filtration rate was 45.9 ± 18.9 mL/min/1.73 m(2), and the median albumin/creatinine ratio was 26(0-151) mg/g. IASBPD was ≥10 mmHg in 184 patients (28.1%). The factors associated with IASBPD ≥10 mmHg were age, systolic blood pressure levels, history of congestive heart failure, lower levels of high-density lipid cholesterol and higher use of hypertensive drugs. Fifty-eight patients (8.5%) developed a CV event during the follow-up. IASBPD ≥10 mmHg [HR, 1.802, 95%CI (1.054-3.079); P = 0.031] was an independent predictor of CV events. CONCLUSIONS Increased IASBPD is an independent predictor of CV events in CKD patients.
Collapse
Affiliation(s)
- Borja Quiroga
- Nephrology Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Isabel Galán
- Nephrology Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | | | - Marian Goicoechea
- Nephrology Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Úrsula Verdalles
- Nephrology Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - José Luño
- Nephrology Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| |
Collapse
|
14
|
Quiroga B, Verdalles Ú, Reque J, García de Vinuesa S, Goicoechea M, Luño J. Cardiovascular events and mortality in chronic kidney disease (stages I-IV). Nefrologia 2013; 33:539-545. [PMID: 23897186 DOI: 10.3265/nefrologia.pre2013.may.11895] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/21/2013] [Indexed: 06/02/2023] Open
Abstract
INTRODUCTION Cardiovascular events (CV) are the major cause of mortality in chronic kidney disease patients (CKD). The aim of the present study was to determine the independent predictors of CV and mortality in CKD patients (stages 1-4). METHODS A prospective study was conducted with 218 patients (62% male), with a median age of 69 years (interquartile range 56-78). Basally, demographic variables, CV risk factors and biochemical values were collected. During follow-up, new CV events and deaths were collected (final variable). RESULTS During follow-up (38 [37-39] months), 50 patients suffered a final event: 37 patients (17%) had a CV and 13 (6%) died due to a non-CV death. Having a final event was associated to male sex, smoker, diabetes mellitus, history of CV event, low diastolic blood pressure values, low glomerular filtration, urine albumin/creatinine higher than 1000 mg/g, higher troponin T levels, higher BNP levels, higher CRP levels and lower haemoglobin levels. Multivariate analysis, showed that only male sex, diabetes mellitus, previous CV event and lower glomerular filtration independently predicted having the final event. CONCLUSION Male sex, diabetes mellitus, previous CV event and lower glomerular filtration independently predicted having a CV event or death in CKD patients. We could not demonstrate the superiority of emerging CV risk markers compared to the classic ones.
Collapse
Affiliation(s)
- Borja Quiroga
- Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
| | | | | | | | | | | |
Collapse
|
15
|
Goicoechea M, Quiroga B, García de Vinuesa S, Verdalles Ú, Reque J, Panizo N, Arroyo D, Santos A, Macías N, Luño J. Intraindividual Interleukin-6 Variations on the Cardiovascular Prognosis of Patients with Chronic Renal Disease. Ren Fail 2012; 34:1002-9. [DOI: 10.3109/0886022x.2012.696469] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
|